knowledge -WSS

knowledge

author：entertainment 2025-09-27 22:56:55 - browse：65

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： FDA clears AI tool for detecting skin cancer

WSS

Weight loss drugs aren’t covered by Obamacare. That may change

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Independent physicians launch a new lobbying group

MD Anderson's Padmanee Sharma responds to research credit suit

Humana cuts profit projections as Medicare Advantage costs soar

knowledge

knowledge

focus

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage enrollment grows 7.1% to 33.4 million people

The cancer drug shortage isn’t new — and neither are the solutions

How digital therapeutics firms are pivoting after Pear's bankruptcy

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Activists slam private health insurers over coverage restrictions

My yearlong odyssey to get my son’s ADHD medication covered

Drug repurposing or repositioning? The language matters

eGenesis tests gene

focus

Medicare Advantage enrollment grows 7.1% to 33.4 million people

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Research misconduct: Proposed new rules face resistance

Obamacare plans could cover weight loss drugs

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Medicare Advantage enrollment hits roughly 33.4 million

focus

entertainment

Wikipedia

explore